对维奈克拉联合阿扎胞苷有应答后停止治疗的急性髓系白血病患者的结局
该回顾性分析纳入62例初诊和22例形态学复发或难治的急性髓系白血病患者,这些患者因耐受性差而停用维奈克拉或维奈克拉联合阿扎胞苷。初诊队列中停用两种药物与继续阿扎胞苷单药者结局相同,微小残留病阴性者2年无治疗生存率为80%;复发或难治队列中既往治疗周期数和IDH突变与总生存相关。
要点
- 初诊队列停用维奈克拉联合阿扎胞苷与继续阿扎胞苷单药者结局相同。
- 初诊队列微小残留病阴性者2年无治疗生存率为80%。
- 复发或难治队列中既往维奈克拉联合阿扎胞苷周期数与无治疗生存显著相关。
核心结论
- 本研究提示,达到缓解后停止治疗的患者结局良好,支持开展前瞻性对照试验的依据。
研究设计与样本
- 回顾性分析因耐受性差而停用维奈克拉或维奈克拉联合阿扎胞苷的患者,包括62例初诊急性髓系白血病和22例形态学复发或难治急性髓系白血病。
主要发现
- 初诊队列(n=62)中28例停用维奈克拉联合阿扎胞苷,34例继续阿扎胞苷单药;中位随访23个月(IQR,20-32),中位总生存和无治疗生存分别为44个月(IQR,16-未达到)和16个月(IQR,8-27)。
- 初诊队列中停用两种治疗与继续阿扎胞苷单药的患者结局相同,微小残留病阴性与2年无治疗生存率80%相关。
- 复发或难治队列(n=22)中位总生存和无治疗生存分别为19个月(IQR,17-31)和10个月(IQR,5-未达到);既往维奈克拉联合阿扎胞苷周期数和IDH突变与总生存增加相关,唯一显著影响无治疗生存的因素是既往周期数。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed the outcome of patients who discontinued venetoclax or venetoclax-azacitidine due to poor tolerance. Sixty-two newly diagnosed (ND) AML patients and 22 patients with morphological relapse or refractory AML were included. In the ND cohort (n = 62), 28 patients stopped venetoclax and azacitidine and 34 patients continued azacitidine monotherapy. With a median follow-up of 23 months (IQR, 20-32), median overall survival and treatment-free survival were 44 (IQR, 16-NR) and 16 (IQR, 8-27) months, respectively. Patients who stopped both treatments and those who continued azacitidine monotherapy had the same outcomes. Negative minimal residual disease was associated with a 2-year treatment-free survival of 80%. In the RR cohort (n = 22), median overall survival and treatment-free survival were 19 (IQR, 17-31) and 10 (IQR, 5-NR) months, respectively. Prior number of venetoclax-azacitidine cycles and IDH mutations were associated with increased overall survival. The only factor significantly impacting treatment-free survival was the number of prior cycles. This study suggests that patients who discontinued treatment in remission have favorable outcomes supporting the rationale for prospective controlled trials.
引用
- Garciaz S, Dumas PY, Bertoli S, et al. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. Am J Hematol. 2024. PMID: 38899566. doi:10.1002/ajh.27417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。